FDA OKs Bone Drug to Prevent Fracture in Certain Cancer Patients
Prolia can be used in some cases of prostate cancer and breast cancer
MONDAY, Sept. 19 (HealthDay News) -- The U.S. Food and Drug Administration has expanded approval for the Amgen bone-building drug Prolia (denosumab) to include prostate cancer or breast cancer patients who are taking certain hormonal therapies.
The drug was initially approved in 2010 to help prevent osteoporosis in post-menopausal women.
Breast cancer patients who use a class of hormone therapy known as aromatase inhibitors to limit estrogen production, and prostate cancer patients who are treated with hormones that limit production of androgens (including testosterone), may be at greater risk of bone fracture.
Amgen is based in Thousand Oaks, Calif.
The FDA has more about this drug.Scott Roberts Related Articles
- New Test Helps Diagnose Type 1 Diabetes
August 21, 2014
- Many Women Who Have Mastectomy Don't Get Breast Reconstruction: Study
August 20, 2014
Learn More About Sharp
Sharp HealthCare is San Diego's health care leader with seven hospitals, two medical groups and a health plan. Learn more about our San Diego hospitals, choose a Sharp-affiliated San Diego doctor or browse our comprehensive medical services.
Copyright © 2011 HealthDay. All rights reserved.